Technical Analysis for ESPR - Esperion Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 43.0 -0.23% -0.10
ESPR closed down 0.23 percent on Wednesday, January 16, 2019, on 69 percent of normal volume.
6 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ESPR trend table...

Date Alert Name Type % Chg
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 16 Crossed Above 20 DMA Bullish 0.00%
Jan 16 Outside Day Range Expansion 0.00%
Jan 15 20 DMA Resistance Bearish -0.23%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.23%
Jan 15 Narrow Range Bar Range Contraction -0.23%
Jan 15 NR7 Range Contraction -0.23%
Jan 15 Inside Day Range Contraction -0.23%
Jan 14 Fell Below 20 DMA Bearish 1.03%
Jan 14 180 Bearish Setup Bearish Swing Setup 1.03%

Older signals for ESPR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Is ESPR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 12 Esperion Therapeutics: Buy, Sell Or Hold?
Jan 11 For Esperion Therapeutics, 2019 Could Be a Big Year
Jan 7 Update: Lawsuit for Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced by Shareholders Foundation
Jan 7 Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Jan 6 All the Pre-JPM News Healthcare Investors Need to Know
Jan 4 Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today
Jan 4 Microcaps mostly among midday movers
Jan 4 Esperion inks deal with Daiichi Sankyo Europe to commercialize bempedoic acid in Europe
Jan 4 Esperion to receive $300 million in upfront payments in deal with Daiichi Sankyo
Jan 4 Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
See more ESPR news...
Indicators
Indicator Value
52 Week High 82.68
52 Week Low 33.06
Average Volume 757,436
200-Day Moving Average 47.8138
50-Day Moving Average 48.4158
20-Day Moving Average 42.967
10-Day Moving Average 42.405
Average True Range 2.7695
ADX 15.05
+DI 19.0032
-DI 23.9014
Chandelier Exit (Long, 3 ATRs ) 42.5215
Chandelier Exit (Short, 3 ATRs ) 46.3885
Upper Bollinger Band 46.9573
Lower Bollinger Band 38.9767
Percent B (%b) 0.5
BandWidth 18.573789
MACD Line -1.5072
MACD Signal Line -1.7484
MACD Histogram 0.2412
Fundamentals Value
Market Cap 973.34 Million
Num Shares 22.6 Million
EPS -5.77
Price-to-Earnings (P/E) Ratio -7.45
Price-to-Sales 0.00
Price-to-Book 6.37
PEG Ratio -4.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.27
Resistance 3 (R3) 45.26 44.49 44.89
Resistance 2 (R2) 44.49 43.92 44.50 44.76
Resistance 1 (R1) 43.75 43.56 43.37 43.76 44.64
Pivot Point 42.98 42.98 42.79 42.99 42.98
Support 1 (S1) 42.24 42.41 41.86 42.25 41.36
Support 2 (S2) 41.47 42.05 41.48 41.24
Support 3 (S3) 40.73 41.47 41.11
Support 4 (S4) 40.74